Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11310945 | 0.90 | LCK (0.58) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL6743024 | 0.90 | LCK (0.58) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL3617721 | 0.90 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL7178003 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL10712499 | 0.86 | LCK (0.59) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL2366676 | 0.86 | KDM4E (0.51) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL1743592 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL31535290 | 0.86 | LCK (0.65) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL31096338 | 0.86 | LCK (0.59) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL7802404 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50527-E1 | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | ALIVEXIS, INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116583286-A | Tetrahydrothienopyrimidine sulfonamide compounds | 某久拉斯株式会社 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| US-6110934-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-1025087-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999052857-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-21 | — | — | WO | disclosed |
| CN-1222145-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | CN | disclosed |
| WO-1999021836-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | WO | disclosed |
| EP-0906283-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-4935511-A | Nervous system, gastrointestinal disorders | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | TYMS, TYMP, TPMT | ALDH1A1 2342/4885KDM4E 153/4885HPGD 512/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | ALDH1A1 2706/4885KDM4E 1936/4885HPGD 1067/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALDH1A1 914/4885KDM4E 2535/4885HPGD 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.